Press release
October 8, 2026
Biohaven Enters Strategic Licensing Agreement with Ono Pharma for Extracellular IgG Degraders in Japan and Select Asian Regions, Lead Candidate BHV-1300 in Phase 3 for Graves' Disease
Biohaven Ltd. (BHVN)
We couldn't retrieve the full text for this release. Read it on the company's site.